Semaglutide's Blood Sugar Control in Dialysis Patients Under Investigation
Background
Managing Type 2 Diabetes Mellitus in patients with End Stage Renal Disease (ESRD) who are on chronic dialysis presents significant challenges due to complex metabolic changes and increased risk of hypoglycemia. Current treatment options often require careful titration and monitoring. This study addresses the crucial knowledge gap regarding the efficacy and safety of semaglutide for glucose management in this specific, high-risk patient population.
Results
As this study is currently ACTIVE_NOT_RECRUITING, specific results are not yet available. However, the primary objective is to determine if semaglutide can significantly improve glucose time in range – the percentage of time a person's blood sugar stays within a healthy target – compared to placebo in this vulnerable patient group. Researchers hypothesize that participants receiving semaglutide will demonstrate a higher percentage of time within their target glucose range. This will be meticulously assessed through continuous glucose monitoring (CGM) data collected over five distinct 10-day periods throughout the 13-month intervention. > The most critical finding will be whether semaglutide can provide a statistically significant improvement in glucose time in range for patients with Type 2 Diabetes and End Stage Renal Disease on Dialysis, potentially offering a new therapeutic avenue.
Why It Matters
If successful, this study could establish semaglutide as a safe and effective treatment option for glucose control in patients with Type 2 Diabetes and End Stage Renal Disease on dialysis. This is a particularly challenging patient group where treatment options are limited and outcomes can be poor. Positive results could lead to a significant improvement in the quality of life and long-term health outcomes for these patients, potentially reducing complications associated with poorly controlled diabetes. The findings will inform future clinical guidelines and potentially pave the way for broader clinical adoption of semaglutide in this specific population.